Back
BioLife Solutions 10K Form
Buy
59
BLFS
BioLife Solutions
Last Price:
$24.95
Seasonality Move:
12.97%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-10 | 10Q | BLFS/BioLife Solutions Quarterly |
2023-11-09 | 10Q | BLFS/BioLife Solutions Quarterly |
2023-08-09 | 10Q | BLFS/BioLife Solutions Quarterly |
2023-05-11 | 10Q | BLFS/BioLife Solutions Quarterly |
2022-11-09 | 10Q | BLFS/BioLife Solutions Quarterly |
2022-08-09 | 10Q | BLFS/BioLife Solutions Quarterly |
Receive BLFS News And Ratings
See the #1 stock for the next 7 days that we like better than BLFS
BLFS Financial Statistics
Sales & Book Value
Annual Sales: | $82.3M |
---|---|
Cash Flow: | $583K |
Price / Cash Flow: | 232.96 |
Annual Sales: | $7.44 |
Price / Book: | 3.33 |
Profitability
EPS (TTM): | -0.45000 |
---|---|
Net Income (TTM): | $-20.2M |
Gross Margin: | $53.7M |
Return on Equity: | -6.05% |
Return on Assets: | -5.12% |
BioLife Solutions Earnings Forecast
Key BioLife Solutions Financial Ratios
-
The Gross Profit Margin over the past 36 years for BLFS is 65.25%.
-
The Selling, General & Administrative Expenses for BLFS have been equal to 60.97% of Gross Profit Margin.
-
The Research & Development expenses have been 9.62% of Revenue.
-
The Net Earning history of BLFS is -24.54% of Total Revenues.
-
Per Share Earnings over the last 36 years have been positive in 16 years.
BioLife Solutions Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Life Sciences Tools & Services |
Sector: | Health Care |
Current Symbol: | BLFS |
CUSIP: | 09062W |
Website: | biolifesolutions.com |
Debt
Debt-to-Equity Ratio: | 0.05 |
---|---|
Current Ratio: | 4.54 |
Quick Ratio: | 3.48 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 169.09 |
BLFS Technical Analysis vs Fundamental Analysis
Buy
59
BioLife Solutions (BLFS)
is a Buy
Is BioLife Solutions a Buy or a Sell?
-
BioLife Solutions stock is rated a BuyThe current BioLife Solutions [BLFS] share price is $24.80. The Score for BLFS is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.